An Eight-Week Study to Evaluate the Efficacy and Safety of SR58611A in Patients With Generalized Anxiety Disorder
Status:
Completed
Trial end date:
2007-04-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the efficacy and safety of SR58611A in patients with
Generalized Anxiety Disorder. The primary objective is to evaluate the efficacy of a 350 mg
and 700 mg dose of SR58611A compared to placebo in patients with generalized anxiety disorder
(GAD). The secondary objectives are to evaluate the efficacy of SR58611A on disability and
quality of life in patients with GAD and to evaluate safety of SR58611A